1. Introduction {#sec1}
===============

Hepatitis B virus (HBV) infection remains a major public health issue \[[@B1]\]. In the United States, an estimated 847,000 persons are living with chronic hepatitis B virus (HBV) infection \[[@B2]\], with about 14,000 attributable deaths annually \[[@B3]\]. Approximately one in four persons living with chronic HBV infection will die prematurely from liver cirrhosis, hepatocellular carcinoma, or liver failure \[[@B4]\].

Serologic testing for hepatitis B surface antigen (HBsAg) is the primary way to identify persons with HBV infection. The Advisory Committee on Immunization Practices (ACIP) recommends that all pregnant women receive HBsAg testing during each pregnancy to identify infants needing postexposure prophylaxis \[[@B5]\]. There are approximately 25,000 infants born to HBsAg-positive pregnant women annually \[[@B6]\], and, without intervention, transmission can occur in up to 85% of exposed infants; among infected infants approximately 90% will become chronically HBV-infected \[[@B5], [@B7]\]. Infants born to HBsAg-positive women should receive hepatitis B vaccine and hepatitis B immunoglobulin (HBIG) within 12 hours of birth, followed by completion of the hepatitis B vaccine series and postvaccination serologic testing \[[@B5]\]. Postexposure prophylaxis is up to 95% effective in preventing HBV transmission among infants born to HBsAg-positive mothers \[[@B8], [@B9]\]. While prophylaxis has been successful in reducing maternal-to-child HBV transmission, there has been little support to address healthcare needs of mothers with HBV infection \[[@B10]\].

Prior studies have used claims data to study hepatitis B using International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes to identify persons with HBV who have liver cirrhosis \[[@B11]\] and antiviral treatment rates during pregnancy among women with HBV \[[@B12]\]. Claims data have also been used to assess the proportion of pregnant women receiving HBsAg testing \[[@B13]\]. We are not aware of previous studies that evaluated the complete HBV care continuum, from testing to linkage to care and treatment, among pregnant and postpartum women using claims data.

As a first step to address gaps in the HBV care continuum for pregnant women with HBV infection, we used commercial claims data to describe HBsAg testing during pregnancy and assess whether pregnant women with hepatitis B are linked to recommended care and antiviral treatment pre- and postdelivery.

2. Methods {#sec2}
==========

2.1. Data Source and Study Population {#sec2.1}
-------------------------------------

We obtained demographic, enrollment, and insurance claims data from Truven Health\'s MarketScan Commercial Claims and Encounters insurance claims database, for women aged 10 to 50 years, from January 1, 2011, through June 30, 2014. This database includes claims for millions of persons with private insurance under the age of 65 years. A unique enrollee identification number allows linkage of medical claims with outpatient pharmacy claims data. This secondary analysis of deidentified insurance claims data did not require ethics approval.

To identify unique pregnancies during the study period, we searched medical claims for delivery-related diagnosis and procedure codes \[[@B12]\]. We defined the delivery index date for each pregnancy as the first service date on which a delivery-related code was documented. During the study period, women could have multiple unique pregnancies and associated delivery index dates, if all other study inclusion criteria were met. Specifically, for pregnancies to be included in the study, women were required to be continuously enrolled both 42 weeks before and 6 months following the delivery index date.

2.2. HBV Testing and Care Continuum Description and Statistical Analysis {#sec2.2}
------------------------------------------------------------------------

To evaluate HBV testing, care, and treatment during pregnancy, we searched both inpatient and outpatient insurance claims for Current Procedural Terminology (CPT) codes, International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) procedure codes, and ICD-9-CM diagnosis codes associated with each cascade step ([Table 1](#tab1){ref-type="table"}). We first calculated the proportion of all unique pregnancies with a claim for at least one HBsAg test during the 42-week period prior to the delivery index date and also used the Cochran--Armitage test for trend to examine differences in HBsAg testing rates with each subsequent pregnancy.

We then described the HBV care continuum among all pregnancies in which the mother was diagnosed with chronic HBV, defined as at least one chronic HBV ICD-9-CM diagnosis code (070.22, 070.23, 070.32, 070.33, or V02.61) documented on a claim prior to the delivery index date. Pregnancies with at least one HIV diagnosis code (795.71, V08, 042, or 079.53) documented on a claim prior to delivery were excluded because we sought to evaluate the HBV care continuum for HBV monoinfected women. We defined engagement in HBV-directed care as an alanine aminotransferase (ALT) test in conjunction with either an HBV DNA or hepatitis B e antigen (HBeAg) test, either before (up to 42 weeks before) or after (up to 6 months after) the delivery index date, and calculated the proportion of HBV-infected pregnancies in which the mother was engaged in care. Among a subset of pregnancies with pharmacy claims available for review, we calculated the proportion of HBV-infected pregnancies in which the mother initiated HBV treatment, defined as at least one claim for antiviral treatment (tenofovir, entecavir, lamivudine, adefovir, or telbivudine) either before or after the delivery index date.

We fit simple logistic regression models, with general estimating equations to account for women with multiple pregnancies, to evaluate the differences in characteristics between pregnancies in which women did or did not receive recommended HBV care. Analyses were completed using SAS, version 9.3 (Cary, North Carolina). Statistical tests were considered significant at *p* \< 0.05.

3. Results {#sec3}
==========

There were 870,888 unique pregnancies (819,752 women) included ([Figure 1](#fig1){ref-type="fig"}). Of these, 714,830 (82%) had at least one HBsAg test claim prior to delivery. This proportion decreased with subsequent pregnancies (*p* \< 0.0001, [Table 2](#tab2){ref-type="table"}). HBsAg testing was more often performed in pregnancies occurring among women aged 20 to 39 years, residing in the North and South Central US, located in urban areas, and with a preferred provider organization (PPO) plan ([Table 2](#tab2){ref-type="table"}). Lower HBsAg testing proportions were observed in pregnancies among women older than 40 years and those located in the Pacific census division.

We identified 1,190 of 870,888 (0.14%) pregnancies (1146 women) with an associated HBV diagnosis code, and six pregnancies that had an associated HIV diagnosis code were excluded. The proportion of pregnancies during which the mother was diagnosed with HBV increased with increasing age and was higher during pregnancies occurring in urban areas ([Table 3](#tab3){ref-type="table"}). In addition, there were a higher proportion of pregnancies during which the mother was diagnosed with HBV in the Pacific and Middle Atlantic census divisions ([Table 3](#tab3){ref-type="table"}).

Among the 1,190 pregnancies with an HBV diagnosis code, 505 received HBV-directed care. The proportion of pregnancies with HBV-directed care was similar predelivery and postdelivery (501 \[42%\] and 463 \[39%\], resp.). While there were geographic differences noted among pregnancies with HBV-directed care (with the greatest engagement in care among those in the West North Central and New England regions and the least engagement in care among those in the East North Central and Middle Atlantic regions), there were no significant differences by age groups, urbanicity, or insurance plan type of the women at the time of the pregnancy ([Table 3](#tab3){ref-type="table"}).

Of the 1,190 pregnancies with an HBV diagnosis code, 975 (81.9%) had pharmacy claims available for review. Antiviral treatment was prescribed during 144 (15%) of these 975 pregnancies: predelivery in 128 (13%) and postdelivery in 16 (1.6%) ([Table 4](#tab4){ref-type="table"}). There were no significant differences in maternal demographic characteristics for antiviral prescription status. Tenofovir (76%) was the most commonly prescribed antiviral medication followed by lamivudine (10%) and entecavir (9%); adefovir and telbivudine make up the remaining 5%.

4. Discussion {#sec4}
=============

Using commercial claims data, we evaluated HBsAg testing practices and the HBV care continuum among commercially insured pregnant women. Most pregnancies (82%) had HBsAg test claim and 1,190 (0.14%) had an HBV diagnosis code. Our data demonstrated a gap in linkage to care among commercially insured pregnant women with HBV, as only 42% of pregnancies had claims suggesting HBV-directed care engagement. Furthermore, while an estimated 25% of persons with chronic HBV infection are treatment eligible, our study showed only 13% of pregnancies with an HBV diagnosis code were prescribed an antiviral prior to delivery, and 1.6% had an antiviral prescription postdelivery; however, we did not assess treatment eligibility (e.g., HBV DNA \> 200,000 IU/mL) among these pregnancies.

Of a population of pregnant women with private health insurance, we showed many pregnancies (18%) without evidence of HBsAg test claim. CDC recommends that all pregnant women should be tested for HBsAg during an early prenatal visit (e.g., first trimester) in each pregnancy, even if they have been previously vaccinated or tested \[[@B5]\]. Testing provides documentation of the positive HBsAg test result and helps to ensure that infants will be identified for timely prophylaxis \[[@B5]\]. Previous data using MarketScan showed that 12% of insured pregnant women did not receive HBsAg testing \[[@B13]\], which differed from our data, possibly due to methodologic differences in amount of time in continuous enrollment (15 months in our study versus 12 months) and age groups included (10--50 years in our study versus 15--44 years). We also included more years of data (2011--2014 versus 2013-2014). Our analysis showed that women aged 20--39 years had higher testing proportions than women aged 40 years or older. This is consistent with the decreased proportion of women receiving HBsAg testing in subsequent pregnancies. While it is reassuring that a large proportion of pregnant women receive HBsAg testing, strategies are needed to get closer to 100% HBsAg testing.

Nationally and regardless of pregnancy status, few persons with HBV are linked to care and many public health efforts are underway to fill this gap \[[@B14], [@B15]\]. Even though a large number of pregnant women received HBsAg testing, many HBsAg-positive women were not linked to care \[[@B10]\]. Our data indicated that 58% of pregnancies with an associated HBV diagnosis code were not linked to appropriate HBV care either during pregnancy or postpartum. There were geographic differences for linkage to care; however, there were not significant differences for HBV linkage to care identified during pregnancy in urban versus nonurban areas. In addition to reducing maternal-to-child transmission, HBsAg testing during pregnancy provides an opportunity to link women to care. Linking HBsAg-positive pregnant women to HBV-directed care is the critical second step in the care continuum to identify those who may benefit from antiviral therapy which can delay HBV-associated liver complications and prevent maternal-to-child transmission.

In addition to prophylaxis for infants born to HBsAg-positive women, pregnant women with HBV may require antiviral treatment. The American Association for the Study of Liver Diseases (AASLD) guidelines suggest maternal antiviral therapy when the maternal HBV DNA is \> 200,000 IU/mL \[[@B16]\]. Regarding antiviral treatment prescriptions, a prior analysis using commercial claims data showed a 13% antiviral prescription rate overall among pregnant women, which was significantly lower than that among nonpregnant women (20%) with HBV \[[@B12]\]. About 25% of persons with HBV are eligible for antiviral therapy \[[@B14]\]. Our data showed that 15% of pregnant women with an HBV diagnosis code were prescribed an antiviral overall and only 1.6% were prescribed an antiviral postdelivery. Tenofovir is first-line antiviral medication for treatment eligible pregnant women, although lamivudine or telbivudine has also been used as there is no evidence of adverse outcomes in infants born to mothers treated with these agents \[[@B16]\]. Although 11 pregnant women were treated with entecavir predelivery, entecavir is not recommended because the safety during pregnancy is not known. Our analysis showed that tenofovir was most commonly used, followed by lamivudine and entecavir. We did not include interferon in our analysis because it is contraindicated during pregnancy. Even though our analysis included claims data between 2011 and 2014, which is prior to the publication of updated AASLD clinical guidelines in 2016 \[[@B16]\], our analysis demonstrated significant linkage to care and treatment gaps among pregnant women with HBV.

Our analysis was subject to at least five limitations. First, we used a commercially insured claims database that does not include women without insurance and therefore does not represent the general US population. The HBV care continuum among under- or uninsured women and children still needs to be characterized to better target public health interventions. Second, there may have been misclassification related to claim codes used to identify pregnant women. For instance, if a claim was not submitted or reimbursed, it may not have been captured in the dataset, thereby leading to an underestimated sample. Third, there was potential for misclassification of HBsAg testing. We included a broad set of codes to include all potential HBV diagnoses; however, codes may have not equated to actual HBV infection as we were unable to confirm infection status with laboratory results or medical record review. Fourth, not all women had prescription claims data available for analysis, which may have led to an underestimated proportion of women receiving antiviral prescriptions. Fifth, we were not able to ascertain the proportion of pregnancies that would have been eligible for treatment, such as those with HBV DNA \> 200,000 IU/mL, because we did not have laboratory data. In addition, since we defined care engagement as having one ALT, HBV DNA, or HBeAg, we were unable to assess continued follow-up care beyond initial care engagement. However, our results are consistent with other published data \[[@B12]\].

There have been several strategies identified that lead to increased testing and linkage to care for persons with HBV that may be applied to address gaps for pregnant women with HBV infection identified in this study. Patient education has shown success by facilitating increased HBV testing in hard to reach populations \[[@B15], [@B17], [@B18]\] and can be applied to pregnant women. In addition, provider education is important to ensure HBV testing is performed and correctly interpreted, and persons with positive results receive appropriate management \[[@B19]\], which can be applied to prenatal care clinics. Coordination of care through care managers or peer navigators has been shown to increase linkage to care \[[@B15], [@B20]\] and can be applied postdelivery to mothers identified with HBV. Utilization of health information technology may increase hepatitis B testing for pregnant women and prompt the provider to order appropriate HBV tests both pre- and postdelivery \[[@B21]\]. Further study is warranted to identify best practice strategies to increase linkage to care for pregnant women with HBV infection.

5. Conclusion {#sec5}
=============

Commercial claims data can be used to evaluate the hepatitis B care continuum among commercially insured pregnant women. Our data showed that many pregnant women received predelivery hepatitis B testing; however testing should approach 100% among a commercially insured population. Furthermore we identified gaps in the hepatitis B care continuum among HBV-infected women which highlight potential targets for public health interventions to decrease HBV-associated morbidity and mortality among pregnant women and their infants.
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###### 

Procedure^a^ and diagnosis codes^b^ used to identify hepatitis B diagnosis, testing, care, and treatment.

  Test or condition       Code number                                                                                                 Code description
  ----------------------- ----------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  HBsAg test^a^           87340                                                                                                       Hepatitis B surface antigen
  80055                   Obstetric panel                                                                                             
  80074                   Acute hepatitis panel                                                                                       
                                                                                                                                      
  HBV^b^                  070.22                                                                                                      Chronic viral hepatitis B with hepatic coma without hepatitis delta
  070.23                  Chronic viral hepatitis B with hepatic coma with hepatitis delta                                            
  070.32                  Chronic viral hepatitis B without mention of hepatic coma without mention of hepatitis delta                
  070.33                  Chronic viral hepatitis B without mention of hepatic coma with hepatitis delta                              
  V02.61                  Hepatitis B carrier                                                                                         
                                                                                                                                      
  ALT test^a^             80076                                                                                                       Hepatic Function Panel
  84460                   Alanine Aminotransferase (ALT)                                                                              
                                                                                                                                      
  HBV DNA test^a^         87515                                                                                                       Hepatitis B virus detection by nucleic acid using direct probe technique
  87516                   Hepatitis B Virus DNA, Qualitative, Real-Time PCR                                                           
  87517                   Hepatitis B Virus DNA, Quantitative, Real-Time PCR                                                          
                                                                                                                                      
  HBeAg test^a^           87350                                                                                                       Hepatitis Be Antigen
                                                                                                                                      
  Newborn live birth^b^   V30--V39                                                                                                    Live born infants according to type of birth
                                                                                                                                      
  HBIG administered^a^    J1573                                                                                                       Injection, hepatitis b immune globulin
  90371                   Hepatitis B immune globulin                                                                                 
                                                                                                                                      
  Hep B vaccine^a^        90739                                                                                                       Hepatitis B vaccine (HepB), adult dosage, 2 dose schedule, for intramuscular use
  90740                   Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (3 dose schedule), for intramuscular use   
  90743                   Hepatitis B vaccine, adolescent (2 dose schedule), for intramuscular use                                    
  90744                   Hepatitis B vaccine, pediatric/adolescent dosage (3 dose schedule), for intramuscular use                   
  90746                   Hepatitis B vaccine, adult dosage (3 dose schedule), for intramuscular use                                  
  90747                   Hepatitis B vaccine, dialysis or immunosuppressed patient dosage (4 dose schedule), for intramuscular use   

^a^Current Procedural Terminology or Healthcare Common Procedure Coding System. ^b^International Classification of Diseases, Ninth Edition, Clinical Modification.

###### 

Hepatitis B screening among 870,888 pregnancies in commercial insurance claims data, 2011--2014.

                                        HBsAg^a^ tested           
  ------------------------ ------------ ----------------- ------- -------------
  Total                    870,888^b^   714,830           82.08    
  Pregnancy                                                       **\<0.001**
   1st pregnancies         795,870      655,218           82.33    
   2nd pregnancies         73,247       58,359            79.67    
   3rd pregnancies         1,743        1,236             70.91    
   4th pregnancies         28           17                60.71    
  Age group                                                       **\<0.001**
   19 or younger           39,067       28612             73.24    
   20 to 29                356,474      300727            84.36    
   30 to 39                438,844      363708            82.88    
   40 or older             36,503       21783             59.67    
  Census division^d^                                              **\<0.001**
   New England             40,403       32,767            81.10    
   Middle Atlantic         102,312      80,774            78.95    
   East North Central      161,920      130,865           80.82    
   West North Central      45,137       38,475            85.24    
   South Atlantic          153,566      128,662           83.78    
   East South Central      52,726       45,441            86.18    
   West South Central      100,916      89,101            88.29    
   Mountain                56,611       47,470            83.85    
   Pacific                 134,756      103,260           76.63    
   Other/unknown           22,541       18,015            79.92    
  Urbanicity^e^                                                   **\<0.001**
   Nonurban                106,490      85,273            80.08    
   Urban                   745,585      613,825           82.33    
  Insurance plan type^f^                                          **\<0.001**
   Managed care^g^         207,179      159,265           76.87    
   PPO or other^h^         637,739      533,989           83.73    

Boldface indicates statistical significance (*p* \< 0.05); ^a^HBsAg = hepatitis B surface antigen. ^b^Among 819,752 women continuously enrolled 42 weeks before and 6 months after first delivery CPT or ICD-9-CM diagnosis code ([Table 1](#tab1){ref-type="table"}).   ^c^Logistic regression models with general estimating equations to account for women with multiple pregnancies during the study period. ^d^New England = CT, MN, MA, NH, RI, VA; Middle Atlantic = NJ, NY, PA; East North Central = IN, IL, MI, OH, WI; West North Central = IA, KS, MN, MO, NB, ND, SD; South Atlantic = DC, DE, FL, GA, MD, NC, SC, VA, WV; East South Central = AL, KY, MS, TN; West South Central = AR, LA, OK, TX; Mountain: AZ, CO, ID, NM, MT, UT, NV, WY; Pacific = AK, CA, HI, OR, WA; and other/unknown = Puerto Rico and unknown state of residence. ^e^Urbanicity was determined by metropolitan statistical area (MSA); 15,732 HBsAg tested of 18,813 (83.6%) were missing urbanicity; ^f^21,576 HBsAg tested of 25,970 (83.1%) were missing insurance plan type. ^g^Health maintenance organizations (HMO), exclusive provider organizations (EPO), and point of Service (POS) plans. ^h^Preferred provider organizations (PPO), high deductible, and comprehensive plans.

###### 

Characteristics of pregnancies by hepatitis B diagnosis and care engagement before and after delivery.

                                                             Pregnancies with HBV diagnosis^a^ engaged^b^ before delivery^c^   Pregnancies with HBV diagnosis engaged after delivery^c^   Pregnancies with HBV diagnosis engaged EITHER before or after delivery^c^                                           
  --------------------- -------- ------ ------ ------------- ----------------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------- ----- ------- ----------- ----- ------- -----------
  Total                 870888   1190   0.14                 501                                                               42.10                                                                                                                                  463   38.91               505   42.44    
  Age group                                    **\<0.001**                                                                                                                                0.064                                                                                     0.246                     0.074
   19 or younger        39067    6      0.02                 0                                                                 0.00                                                                                                                                   0     0.00                0     0.00     
   20 to 29             356473   282    0.08                 126                                                               44.68                                                                                                                                  109   38.65               126   44.68    
   30 to 39             438839   797    0.18                 346                                                               43.41                                                                                                                                  329   41.28               350   43.91    
   40 or older          36503    105    0.29                 29                                                                27.62                                                                                                                                  25    23.81               29    27.62    
  Census division^e^                           **\<0.001**                                                                                                                                **0.003**                                                                                 **0.004**                 **0.004**
   New England          40403    48     0.12                 28                                                                58.33                                                                                                                                  27    56.25               28    58.33    
   Middle Atlantic      102310   210    0.21                 71                                                                33.81                                                                                                                                  65    30.95               71    33.81    
   East North Central   161920   153    0.09                 34                                                                22.22                                                                                                                                  33    21.57               37    24.18    
   West North Central   45137    50     0.11                 35                                                                70.00                                                                                                                                  34    68.00               35    70.00    
   South Atlantic       153565   127    0.08                 56                                                                44.09                                                                                                                                  52    40.94               56    44.09    
   East South Central   52726    29     0.06                 12                                                                41.38                                                                                                                                  9     31.03               12    41.38    
   West South Central   100914   120    0.12                 52                                                                43.33                                                                                                                                  44    36.67               52    43.33    
   Mountain             56610    32     0.06                 15                                                                46.88                                                                                                                                  12    37.50               15    46.88    
   Pacific              134756   401    0.30                 190                                                               47.38                                                                                                                                  181   45.14               191   47.63    
   Other/unknown        22541    20     0.09                 8                                                                 40.00                                                                                                                                  6     30.00               8     40.00    
  Urbanicity^f^                                **\<0.001**                                                                                                                                0.098                                                                                     0.098                     0.091
   Nonurban             106490   33     0.03                 9                                                                 27.27                                                                                                                                  8     24.24               9     27.27    
   Urban                745579   1137   0.15                 482                                                               42.39                                                                                                                                  447   39.31               486   42.74    
   Missing              18813    20     0.11                 10                                                                50.00                                                                                                                                  8     40.00               10    50.00    
  Insurance plan type                          **\<0.001**                                                                                                                                0.193                                                                                     0.117                     0.166
   Managed care^g^      207178   384    0.19                 171                                                               44.53                                                                                                                                  161   41.93               173   45.05    
   PPO or other^h^      637734   786    0.12                 321                                                               40.84                                                                                                                                  295   37.53               323   41.09    
   Missing              25970    20     0.08                 9                                                                 45.00                                                                                                                                  7     35.00               9     45.00    

Boldface indicates statistical significance (*p* \< 0.05). ^a^At least 1 chronic HBV diagnosis code prior to delivery index date among pregnancies without HIV diagnosis. ^b^Defined as HBV DNA and ALT or HBeAG and ALT. ^c^Before (up to 42 weeks before) or after (up to 6 months after) the deliver index date. ^d^Logistic regression models with general estimating equations to account for women with multiple pregnancies during the study period. ^e^New England = CT, MN, MA, NH, RI, VA; Middle Atlantic = NJ, NY, PA; East North Central = IN, IL, MI, OH, WI; West North Central = IA, KS, MN, MO, NB, ND, SD; South Atlantic = DC, DE, FL, GA, MD, NC, SC, VA, WV; East South Central = AL, KY, MS, TN; West South Central = AR, LA, OK, TX; Mountain: AZ, CO, ID, NM, MT, UT, NV, WY; Pacific = AK, CA, HI, OR, WA; and other/unknown = Puerto Rico and unknown state of residence. ^f^Urbanicity was determined by metropolitan statistical area (MSA). ^g^Health maintenance organizations (HMO), exclusive provider organizations (EPO), and point of Service (POS) plans. ^h^Preferred provider organizations (PPO), high deductible, and comprehensive plans.

###### 

Characteristics of 975 hepatitis B diagnosed pregnancies with pharmacy claims by antiviral treatment^a^.

                              Pregnancies with HBV diagnosis treated before delivery^b^   Pregnancies with HBV diagnosis treated after delivery^b^   Pregnancies with HBV diagnosis treated EITHER before or after delivery^b^                                     
  --------------------- ----- ----------------------------------------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------- ---- ------ ------- ----- ------- -------
  Total                 975   128                                                         13.13                                                                                                                                  16   1.64           144   14.77    
  Age group                                                                                                                                          0.631                                                                                   0.062                 0.916
   19 or younger        5     0                                                           0.00                                                                                                                                   0    0.00           0     0.00     
   20 to 29             232   33                                                          14.22                                                                                                                                  1    0.43           34    14.66    
   30 to 39             654   85                                                          13.00                                                                                                                                  14   2.14           99    15.14    
   40 or older          84    10                                                          11.90                                                                                                                                  1    1.19           11    13.10    
  Census division^d^                                                                                                                                 0.284                                                                                   0.347                 0.439
   New England          36    7                                                           19.44                                                                                                                                  1    2.78           8     22.22    
   Middle Atlantic      143   27                                                          18.88                                                                                                                                  1    0.70           28    19.58    
   East North Central   127   10                                                          7.87                                                                                                                                   1    0.79           11    8.66     
   West North Central   44    5                                                           11.36                                                                                                                                  1    2.27           6     13.64    
   South Atlantic       105   13                                                          12.38                                                                                                                                  3    2.86           17    15.18    
   East South Central   27    4                                                           14.81                                                                                                                                  0    0.00           3     11.11    
   West South Central   112   16                                                          14.29                                                                                                                                  1    0.89           13    11.61    
   Mountain             27    3                                                           11.11                                                                                                                                  0    0.00           2     7.41     
   Pacific              346   42                                                          12.14                                                                                                                                  8    2.31           50    14.45    
   Other/unknown        8     1                                                           12.50                                                                                                                                  0    0.00           1     12.50    
  Urbanicity^e^                                                                                                                                      0.422                                                                                   \-\--                 0.333
   Non-urban            26    2                                                           7.69                                                                                                                                   0    0.00           2     7.69     
   Urban                939   125                                                         13.31                                                                                                                                  16   1.70           141   15.02    
   Missing              10    1                                                           10.00                                                                                                                                  0    0.00           1     10.00    
  Insurance Plan Type                                                                                                                                0.405                                                                                   0.162                 0.566
   Managed care^f^      329   49                                                          14.89                                                                                                                                  8    2.43           57    17.33    
   PPO or other^g^      629   78                                                          12.40                                                                                                                                  8    1.27           86    13.67    
   Missing              17    1                                                           5.88                                                                                                                                   0    0.00           1     5.88     

Boldface indicates statistical significance (*p* \< 0.05). ^a^Among 975 of 1190 HBV+ pregnancies where prescription drug claims were available for review. ^b^Before (up to 42 weeks before) or after (up to 6 months after) the deliver index date. ^c^Logistic regression models with general estimating equations to account for women with multiple pregnancies during the study period. ^d^New England = CT, MN, MA, NH, RI, VA; Middle Atlantic = NJ, NY, PA; East North Central = IN, IL, MI, OH, WI; West North Central = IA, KS, MN, MO, NB, ND, SD; South Atlantic = DC, DE, FL, GA, MD, NC, SC, VA, WV; East South Central = AL, KY, MS, TN; West South Central = AR, LA, OK, TX; Mountain: AZ, CO, ID, NM, MT, UT, NV, WY; Pacific = AK, CA, HI, OR, WA; and other/unknown = Puerto Rico and unknown state of residence. ^e^Urbanicity was determined by metropolitan statistical area (MSA). ^f^Health maintenance organizations (HMO), exclusive provider organizations (EPO), and point of service (POS) plans. ^g^Preferred provider organizations (PPO), high deductible, and comprehensive plans.

[^1]: Academic Editor: Lu-Yu Hwang
